AstraZeneca announces WAYPOINT trial met both co-primary endpoints
Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...
EuropaWire3 小时
Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic ...
(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...
Amgen, AstraZeneca announce top-line results from WAYPOINT trial
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
Yahoo Finance6 小时
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with ...
November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP ... significant and clinically ...
Battling Sinus Woes? Here’s How Seasonal Allergies Can Wreak Havoc and What You Can Do ...
Expert says, that by recognising the connection between seasonal changes, allergies, and sinus health, individuals can take ...
Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy
Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...
Buy9 小时
AstraZeneca touts positive results from nasal polyp treatment study
(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.
Sharecast11 小时
AstraZeneca "excited" by positive results in Tezspire clinical trial
compared to a placebo in adults with severe chronic rhinosinusitis with nasal polyps, showed a "statistically significant and ...